Straits Times Index
3,292.69 +10.64 (+0.32%) S&P 500
5,104.11 -12.06 (-0.24%) Dow
38,227.23 -158.86 (-0.41%) Nasdaq
15,941.48 -41.61 (-0.26%) Bitcoin USD
62,955.66 -677.18 (-1.06%) CMC Crypto 200
1,300.23 -38.83 (-2.90%)
Swedish Orphan Biovitrum AB (publ) (SOBI.ST)
| Previous close | 283.40 |
| Open | 283.60 |
| Bid | 286.40 x 0 |
| Ask | 287.00 x 0 |
| Day's range | 282.80 - 287.80 |
| 52-week range | 189.03 - 302.00 |
| Volume | |
| Avg. volume | 574,562 |
| Market cap | 96.998B |
| Beta (5Y monthly) | 0.26 |
| PE ratio (TTM) | 45.16 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- PR Newswire
Sobi® receives positive CHMP opinion recommending approval of efanesoctocog alfa for once-weekly treatment of haemophilia A
Sobi® today announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has issued a positive opinion recommending approval of efanesoctocog alfa, for the treatment and prevention of bleeds and perioperative prophylaxis in haemophilia A. Efanesoctocog alfa is a once-weekly and high-sustained factor VIII replacement therapy for patients of all ages and any disease severity.
- PR Newswire
Sobi Q1 2024 report: Strong sales reflecting the strength of the portfolio
Swedish Orphan Biovitrum AB (publ) (Sobi®) today announced its report for the first quarter 2024
- PR Newswire
Notice of Annual General Meeting in Swedish Orphan Biovitrum AB (publ)
The shareholders in Swedish Orphan Biovitrum AB (publ) (Sobi®) Reg. No. 556038-9321, are hereby summoned to the Annual General Meeting (the "Meeting"), to be held on Tuesday, 14 May 2024 at 15.00 at IVA Konferenscenter, Grev Turegatan 16, Stockholm, Sweden.
